Effects of statins on functional capacity and cardiac remodeling in patients with heart failure and preserved ejection fraction: a randomized open-label pilot trial - Summary - MDSpire

Effects of statins on functional capacity and cardiac remodeling in patients with heart failure and preserved ejection fraction: a randomized open-label pilot trial

  • By

  • Artem Ovchinnikov

  • Alexandra Potekhina

  • Olga Svirida

  • Tatiana Arefieva

  • Tamila Martynyuk

  • Fail Ageev

  • Marijana Tadic

  • Evgeny Belyavskiy

  • July 13, 2026

Share

Objective:

To determine the effects of atorvastatin and rosuvastatin on functional capacity, cardiac remodeling, and biomarkers in patients with HFpEF.

Approach:
  • Study Design: A randomized, open-label, parallel-group, single-center study involving 59 patients with HFpEF.
  • Intervention: Participants received either atorvastatin (20–80 mg/day) or rosuvastatin (10–40 mg/day) for 6 months.
  • Measurements: Echocardiography, 6-minute walk distance (6MWTD), and inflammatory biomarkers were analyzed at baseline and after 6 months.
Key Findings:
  • Atorvastatin showed a greater increase in 6MWTD compared to rosuvastatin.
  • Both statin groups had comparable improvements in NYHA functional class and exercise duration.
  • Atorvastatin was superior in modifying left atrial reserve.
  • Significant decreases in inflammatory biomarkers were observed in the atorvastatin group.
Interpretation:

Limitations:
  • Small sample size of 59 participants.
  • Short duration of 6 months for the intervention.
Conclusion:

Sources:

Original Source(s)

Related Content